TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug

• Overall net revenue from sales in Q1 was $8.3 million, the company said. 
• The company said that it now has funds to sustain itself till the second quarter of 2027.
• Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million.  

Shares of Tonix Pharmaceuticals (TNXP) fell 3% after hours after the company said that it expects a wider preliminary net loss for the first quarter of 2026 and revenue of $3.7 million for its newly launched drug Tonmya.

The company said on Friday that it expects a Q1 net loss of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.

TNXP’s Preliminary Numbers

Q1 net revenue from sales of its treatments Zembrace SymTouch, and Tosymra for the quarter ended March 31, 2026, was approximately $3.2 million, compared to $2.4 million for the quarter ended March 31, 2025.

Net revenue from sales of Tonmya for the quarter was approximately $3.7 million. Tonmya, an FDA-approved, non-opioid medication designed to treat fibromyalgia in adults, was launched in November 2025.

Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million, Tonix said.  

The company said that it ended the first quarter with about $185.5 million in cash and cash equivalents, which, together with net proceeds of $17.4 million that it raised in April 2026 to be enough to sustain it till the second quarter of 2027.

The company is now slated to report its full financial results on May 11.

How Did TNXP Retail Traders React?

On Stocktwits, retail sentiment around TNXP stock stayed in the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.

A Stocktwits user opined that the numbers put forth by Tonix are being “misunderstood” and Tonmya launch is not “as weak as it appears.”

Another user opined that the company entered 2026 with real momentum and a stronger balance sheet than many of its small-cap biotech peers.

TNXP stock fell 25% over the past 12 months. 

Read More: CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data

For updates and corrections, email newsroom[at]stocktwits[dot]com.